Compare STG & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STG | CRDL |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 97.3M |
| IPO Year | 2018 | N/A |
| Metric | STG | CRDL |
|---|---|---|
| Price | $6.05 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 4.2K | ★ 383.5K |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $285,589,112.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.28 | $0.77 |
| 52 Week High | $15.00 | $1.59 |
| Indicator | STG | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 49.59 |
| Support Level | $5.84 | $0.94 |
| Resistance Level | $6.12 | $1.03 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 53.52 | 59.09 |
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.